The Respiratory Effectiveness Group (REG) Summit, which took place on 28–29 June 2014, provided clinicians, general practitioners, pulmonologists, and representatives from the industry with the opportunity to discuss real-life effectiveness research in respiratory disease. This white paper presents research from studies identified of particular relevant to the asthma and COPD markets which revealed:
The potential benefits that Symbicort (budesonide/formoterol; AstraZeneca) may have over Spiriva.
The Value of add-on Spiriva therapy in asthma as Boehringer Ingelheim prepares to expand Spiriva's indications in the EU.
.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: